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Catheter-related infections (CRI) are frequent and manifest in a wide range of clinical
situations. A rational approach is necessary for the adequate management of these
infections. Whenever a CRI is suspected, two main questions have to be addressed:
whether to remove the catheter and whether to initiate empiric antimicrobial treatment.
As the clinical diagnosis of CRI has a low specificity, the catheter should be removed only
in circumstances such as severe or ongoing sepsis, persistent bacteremia, pulmonary or
peripheral embolization, endocarditis, signs of tunnel infection, when the catheters or
when the CRI is caused by fungi, Staphylococcus aureus or Pseudomonas aeruginosa are easy
to replace among others. Exchanging the catheter through a guidewire is a frequent
practice but is not recommended by some authors. Empiric antimicrobial treatment
should be administered in any of the following situations: when the catheter is not
removed, in the case of central venous or surgically implanted catheters and prosthetic
implants, in the presence of severe sepsis, neutropenia or other immunodepressed status,
suppurative phlebitis, embolization and acute endocarditis. Empriic antimicrobial treat-
ment should include a glycopeptide (vancomycin or teicoplanin) as staphylococci are the
most frequent cause of CRI. Adding an antipseudomonal agent, such as amikacin,
aztreonam, ceftazidime, cefepime, piperacillin/tazobactam, or a carbapenem (depending
on the local antimicrobial susceptibility data or antibiotic policy) is necessary in cases of
neutropenia, burn patients, severe sepsis, or suspicion of contaminated infusate. Empiric
treatment against Candida is not initially necessary in most cases. Empiric treatment
should be replaced by specific therapy whenever possible.
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I N T R O D U C T I O N
Intravascular catheter-related infections (CRI) are
among the most frequent types of infections acqui-
red within hospitals, and their prevalence might be
increasing as intravascular catheters are used more
frequently [1]. The term catheter-related infections
includes a wide range of clinical situations, ran-
ging in severity from uncomplicated insertion-
site infections in peripheral catheters to central
venous catheter-related septic shock, endocarditis,
or suppurative phlebitis. In this era of evidence-
based medicine, it is surprising that high-quality
scientific evidence for the management of patients
with suspected CRI is scarce, and that recommen-
dations are mainly based on anecdotal reports,
observational data and the opinions of experts.
The question of a possible CRI frequently arises
when evaluating a patient with an intravascular
catheter who develops fever and in whom an
obvious origin for the fever is not apparent. Such
a situation is frequent in clinical practice. Before
indicating a specific empiric antimicrobial ther-
apy, the physician must try to answer several
key questions. Is CRI a plausible explanation for
the patient’s fever or are there other possible
origins? What should be done for establishing
the diagnosis of CRI? What kind of patient and
clinical situation are involved? Should the catheter
be removed? Is empiric antimicrobial therapy
necessary? A rational approach may lead to more
adequate management of the patients and may
avoid the unnecessary use of antibiotics.
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C L I N I C A L S U S P I C I O N O F C R I
In patients with fever and no evident local inflam-
matory signs, a specific clinical diagnosis for CRI is
rarely established; negative cultures are obtained
in more than 60% of the cases of catheters removed
because of a suspicion of infection [2]. However,
CRI is a frequent cause of fever in these patients
and should always be considered. While patients
may present with fever, nonspecific symptoms and
signs of sepsis, such as chills, rigors, hypotension,
hyperventilation, abdominal pain, vomiting, diar-
rhea, confusion and seizures, the possibility of a
catheter-related origin and should always be con-
sidered; especially in cases of sepsis in low-risk
patients, or when the onset in abrupt or linked
with catheter manipulation or infusion adminis-
tration [3]. Risk factors for CRI must also be taken
into account: long duration of catheterization, lack
of adequate care, emergency insertion, femoral
location, triple-lumen catheter, and frequent mani-
pulation of hubs, among others [1]. Due to the
difficulty in establishing a specific clinical diag-
nosis and in order to avoid unnecessary removal of
catheters (especially central venous catheters and
long-term surgically implanted catheters), diag-
nostic procedures for which the catheter is left in
place are being investigated and implemented in
clinical practice. In patients with a central venous
catheter and without inflammatory signs or puru-
lence at the insertion site, an alternative approach
is exchange to the catheter through a guidewire, so
that the catheter can be sent for culture. This prac-
tice is controversial: while some authors suggest
that in the case of suspected sepsis it should not be
attempted [4], others recommend it as a first step
[5,6]. Nevertheless, the decision whether to initiate
antimicrobial treatment usually must be made
before the results of cultures are available, based
on clinical suspicion and the clinical condition of
the patient.
In other cases, the implication of the catheter as
the cause of the fever is clearer, especially in
patients with inflammation or purulence at the
insertion site (infrequent in central venous cathe-
ters), in patients with signs of subcutaneous tunnel
infection, or in the case of isolation in several sets
of blood cultures of certain micro-organisms fre-
quently causing catheter-related bacteremia, such
as staphylococci (especially coagulase-negative
staphylococci), Corynebacterium, or Candida. A
summary of features suggestive of intravascular
device etiology is shown in Table 1.
I N D I C A T I O N S F O R C A T H E T E R
R E M O V A L
Once the diagnosis of CRI is established or sus-
pected, the question is whether the catheter should
be removed as an initial therapeutic maneuvre or
not. Withdrawal of the catheter implies some
advantages in the management of CRI, such as
removal of the source of the infection and the
possibility of performing catheter culture. If the
catheter is easy to replace (such as peripheral
catheters), catheter removal should always be
undertaken. For uncomplicated localized inser-
tion-site infections of peripheral catheters in low-
risk patients, catheter withdrawal is frequently
adequate to cure the infection.
However, there are circumstances in which
removal of the catheter is difficult or not desirable
unless absolutely necessary. This is the case with
catheters that are surgically implanted, such as
tunneled silicone catheters (Broviac and Hickman
catheters) and subcutaneous infusion ports
(Mediport, Infus-a port, Port-a-Cath), which are
frequently used in oncohematological patients.
Catheter removal is also problematic in patients
with poor venous access, in patients for whom
trying a new catheterization involves unacceptable
risk (e.g. patients with severe thrombocytopenia or
Table 1 Features suggestive of intravascular device-related sepsis
Evidence of inadequate care of insertion site or hubs
Source of sepsis not apparent, no identifiable local infection
Inflammation or purulence at intravascular catheter insertion site
Septicemia caused by typical organisms, such as staphylococci, Corynebacterium, Candida, Fusarium, or Malasezzia species
Outbreak of infusion-associated bloodstream infections caused by Enterobacter species or Serratia marcescens
Onset associated with administration of intravenous infusion
Persistent bacteremia (in the absence of endocarditis) before the catheter is removed
Improvement with removal of catheter and infusion
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other coagulation problems) [8], and in patients
with several catheters in place. There is some
evidence that acute sepsis-related morbidity and
mortality in patients with catheter-related coagu-
lase-negative staphylococci bacteremia are not
influenced by catheter withdrawal, although
catheter retention is associated with a higher risk
of recurrence of the bacteremia [9]. As coagulase-
negative staphylococci are the leading cause of
CRI, catheter retention might be considered initi-
ally in patients for whom catheter removal is
problematic, provided that any of the following
circumstances (which increase the risk of compli-
cations) are not present: signs of subcutaneous
tunnel infection, severe sepsis or septic shock,
peripheral or pulmonary embolization, and data
suggestive of infectious endocarditis. After 48–72 h
of empiric treatment, the need for catheter with-
drawal should be re-evaluated in view of the
clinical response and culture results. Circum-
stances that should prompt catheter removal at
that moment are ongoing sepsis, persistent bacter-
emia, or isolation of micro-organisms associated
with a worse outcome if the catheter was not
replaced, such as Candida spp., Aspergillus, other
fungi, Staphylococcus aureus, Corynebacterium jei-
keium, Bacillus spp., Pseudomonas spp., and rapidly
growing mycobacteria [8,10–14]. Indications for
catheter removal in the case of established or
suspected CRI are summarized in Table 2.
I N D I C A T I O N S F O R E M P I R I C
A N T I M I C R O B I A L T R E A T M E N T
Empiric treatment, when indicated, should pro-
vide coverage against the most frequent organisms
causing CRI [1]. Even though local epidemiology
must be taken into account, certain organisms
should always be considered. Gram-positive cocci
are the leading cause of CRI according to all
studies, being responsible for more than 60% of
episodes. Among them, coagulase-negative sta-
phylococci are the most frequent, followed by S.
aureus and enterococci. Skin Gram-positive bacilli,
such as Corynebacterium and Bacillus species, may
also cause CRI. Gram-negative bacilli (mainly
Pseudomonas aeruginosa, Enterobacter spp., Serratia
spp., Acinetobacter spp., and other nonfermentative
Gram-negative bacilli and enterobacteria) usually
cause about 10–20% of episodes. Candida spp. are
responsible for 2–5% of CRI, although its fre-
quency seems to be increasing, especially in inten-
sive care units. Organisms emerging as catheter-
related pathogens are Micrococcus, Achromobacter,
rapidly growing mycobacteria (M. chelonei, M.
fortuitum), and fungus such as Malassezia furfur,
Rhodotorula, Fusarium, or Trichosporon [8], particu-
larly in predisposed patients, such as neutropenic
individuals or patients suffering from burns.
In view of the microbiology of CRI, empiric
treatment would need to cover a wide spectrum
of organisms, and this would lead to an excessive
and inappropriate use of broad spectrum antimi-
crobials. To avoid, a rational approach is necessary
such misuse; the clinical situation of the patient,
the type and severity of infection, and the circum-
stances that modify the possible etiology must be
taken into account.
Complications associated with CRI are more fre-
quent with central venous catheters and surgically
implanted venous accesses than in peripheral can-
nulae. One out of every three patients with central
venous catheter-related sepsis developed major
complications according to one study [15], includ-
ing septic shock, sustained sepsis, suppurative
phlebitis, metastatic infection, and endocarditis.
Among patients with Hickman catheter-related
infections, 75% of them developed bloodstream
Table 2 Indications for catheter removal in case of suspected or established catheter-related infection (from [10] with
permission)
Easy-to-replace catheters
Signs of tunnel infection extending >2 cm proximally from the catheter exit site
Severe sepsis or septic shock
Ongoing sepsis after 48–72 h of antimicrobial treatment
Persistent bacteremia after 72 h of antimicrobial treatment
Pulmonary embolization or infectious endocarditis
Peripheral embolization
Infection caused by Candida spp., Aspergillus, other fungi, S. aureus, C. jeikeium, Bacillus spp., Pseudomonas spp., and rapidly
growing mycobacteria
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 275–281
Rodrı´guez-Ban˜o Empiric therapy selection in catheter-related infections 277
infections [16]. Thus, empiric antimicrobial treat-
ment is indicated for patients with central venous
catheters or surgically implanted long-term cathe-
ters, due to the high risk of complications. For
patients in whom the catheter is not removed,
antimicrobial therapy should also be initiated [10].
Patients with moderate to severe CRI, such as
those presenting with severe sepsis or septic
shock, suppurative phlebitis, signs of acute endo-
carditis, pulmonary embolization, or metastatic
infection, whatever the type of catheter should
also receive empiric antimicrobials. Finally,
empiric treatment is indicated for neutropenic or
other severely immunodepressed patients and for
patients with endovascular devices or prostheses
(such as prosthetic valves and pacemakers). Some
authors also recommend empiric treatment for
patients with prosthetic orthopedic implants [3].
S. aureus nasal carriers in the intensive care unit
have an increased risk of developing catheter-
associated bacteremia due to this organism, and
the risk is especially high among carriers of methi-
cillin-resistant strains [17]. As long as catheter-
related sepsis due to S. aureus is associated with
increased risk of complications [15], empiric treat-
ment should be considered for these patients.
Indications for empiric treatment in patients with
CRI are given in Table 3.
C H O I C E O F A D E Q U A T E
A N T I M I C R O B I A L A G E N T S F O R
E M P I R I C T R E A T M E N T
Empiric antimicrobial agents may be administered
either systemically, locally (the ‘antibiotic lock’
technique, which is reviewed elsewhere in this
issue) or both ways. Systemic empiric treatment
should be given intravenously. Whenever the
catheter is left in place, the drug should be admi-
nistered through it, and in cases of triple-lumen
catheters, the administration should rotate among
the different lumens.
In view of the microbiology of CRI, an antimi-
crobial agent with activity against Gram-positive
organisms should always be included. Glycopep-
tides are considered the drugs of choice for empiric
treatment as the incidence of methicillin-resistance
is high among coagulase-negative staphylococci
(and among S. aureus in some hospitals). The avail-
able glycopeptides are vancomycin and teicopla-
nin. In vitro data indicate that activity against
S. aureus is similar among both agents and that van-
comycin activity against S. epidermidis is somehow
better [18]. In vitro resistance or intermediate resis-
tance in coagulase-negative staphylococci, partic-
ularly S. hemolyticus, are more frequently described
for teicoplanin than for vancomycin [19], and thus,
knowledge of local epidemiology is important. In
comparative trials, teicoplanin (6 mg/kg/day; the
first three doses are usually administered every
12 h) and vancomycin (15 mg/kg every 12 h; usual
dose, 1 g every 12 h) showed equivalent efficacy in
patients with cancer [20,21]. Other trials have also
shown comparable efficacy in the empiric treat-
ment of neutropenic patients with fever [22,23].
Failures in noncatheter-related S. aureus bactere-
mia or endocarditis have been reported more fre-
quently for patients treated with teicoplanin
(6 mg/kg/day) than in patients treated with van-
comycin [24,25]. In these circumstances, provided
that a glycopeptide is to be used because of beta-
lactam resistance or allergy, vancomycin is of
choice.
The results of some studies have shown that
teicoplanin might be better tolerated than vanco-
mycin, particularly with respect to administration-
related adverse effects (the so-called ‘red man
syndrome’) and renal toxicity [21,22,26]. The clin-
ical relevance of such differences must be weighed
with caution. Most vancomycin-infusion-related
reactions may be avoided if the infusion is admi-
nistered slowly (over 2 h or more). Renal toxicity of
vancomycin is considered uncommon nowadays,
and is reversible if standard doses are used for
Table 3 Situations in which empirical treatment in patients with catheter-related infections is indicated
Central venous catheter or surgically implanted long-term catheters
The catheter is not removed
Severe sepsis, septic shock
Suppurative phlebitis, pulmonary embolization, metastatic infection, acute endocarditis
Neutropenic or immunodepressed patients
Patients with endovascular devices or prosthesis
Patients with orthopedic prosthetic plants – S. aureus nasal carriers in the ICU
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patients with normal renal function or appropri-
ately reduced in the case of renal failure [27]. Renal
toxicity is additive if vancomycin is used in com-
bination with aminoglycosides. Renal insuffi-
ciency and concomitant aminoglycoside use are
indications for monitoring vancomycin levels in
serum. With regard to cost, teicoplanin is more
expensive compared to vancomycin, but indirect
costs associated with teicoplanin use are lower as it
is administered once daily, which might compen-
sate direct costs [28].
Quinupristin/dalfopristin,a semisyntheticstrep-
togramin, might be an alternative to glycopeptides
in the treatment of CRI caused by staphylococci
and enterococci. Although larger trials are requi-
red, in a randomized open phase II trial including
39 patients with catheter-related staphylococcal
bacteremia, quinuprostin/dalfopristin and vanco-
mycin showed similar efficacy and tolerance [29].
Apart from a glycopeptide, an antimicrobial
agent with activity against aerobic Gram-negative
bacilli (including P. aeruginosa) should be added to
the empiric coverage of CRI in neutropenic
patients and in those presenting with severe
sepsis or septic shock. It should also be considered
for burn patients, in whom colonization with
Gram-negative bacilli is frequent, in cases of noso-
comial outbreaks due to specific Gram-negative
organisms (e.g. an Acinetobacter baumannii out-
break in an ICU), and whenever a contaminated
infusate is suspected as the source of the infection.
Several antimicrobial agents might be included in
the empiric antimicrobial regimen: aminoglyco-
sides, aztreonam, third-generation cephalosporins
withantipseudomonal activity, fourth-generation
cephalosporins, piperacillin/tazobactam and qui-
nolones. Local epidemiology and hospital antibio-
tic policy should be considered in every case.
Aminoglycosides and aztreonam (the latter espe-
cially in patients at risk for renal toxicity) are
frequently used, as a complement for the glyco-
peptide activity against Gram-positive organisms
[10].
In patients with total parenteral nutrition and
other risk factors for candidemia (major surgery,
broad spectrum antibiotics, colonization with Can-
dida spp., etc.) empiric treatment against Candida is
sometimes considered. However, empiric treat-
ment of most patients at risk for candidemia can
be initiated without antifungal agents and re-eval-
uated 48 h later, considering the clinical response
and culture results. For the treatment of catheter-
related candidemia, fluconazol may be used [11],
but amphotericin B is the drug of choice for flu-
conazol-resistant species of Candida, such as C.
kruseii or C. glabrata.
In patients with purulent exudate at the inser-
tion site, a Gram stain of the exudate may orient
empiric treatment. In any case, culture results
should lead to specific directed therapy against
the isolated pathogens. Antimicrobial agents used
for the empiric treatment of CRI are shown in
Table 4.
C O N C L U S I O N S
Catheter-related infection is frequently consider-
ed in patients presenting with nosocomial fever
and intravascular catheters. The decision concern-
ing an empiric antimicrobial treatment should
be based on the type of infection, the clinical
condition of the patient and the risk of com-
plications. Systemic empiric treatment should
include the administration of a glycopeptide. In
many cases, an antimicrobial agent with activity
against aerobic Gram-negative bacilli based on
local epidemiology and antibiotic policy should
be added.
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